Hepatitis C treatment

Current Studies in Hematology and Blood Transfusion

Volumn 62, Issue , 1998, Pages 181-207

  Damen, M ^a,c   Bresters, D ^b  

^a CENTRAL LABORATORY   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c Viral Diagnostic Department   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALPHA INTERFERON; ANTIVIRUS AGENT; BETA INTERFERON; RIBAVIRIN; URSODEOXYCHOLIC ACID;

ALOPECIA; ANOREXIA; ANTIVIRAL ACTIVITY; CLINICAL TRIAL; CYTOPENIA; DEPRESSION; DIARRHEA; DRUG EFFICACY; FATIGUE; FLU LIKE SYNDROME; HEMOLYTIC ANEMIA; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INSOMNIA; IRRITABILITY; LETHARGY; LIVER HISTOLOGY; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; META ANALYSIS; NAUSEA; PARESTHESIA; PRIORITY JOURNAL; PRURITUS; RETINA INJURY; REVIEW; SEIZURE; SEXUAL DYSFUNCTION; SKIN DISEASE; SOMNOLENCE; UPPER RESPIRATORY TRACT INFECTION; VERTIGO; VOMITING; WEIGHT REDUCTION;

ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; LIVER TRANSPLANTATION; RETREATMENT; RIBAVIRIN;

EID: 0031931318     PISSN: 02580330     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000060479     Document Type: Article

References (146)

1. Choo Q-L, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M: Isolation of a cDNA clone derived from a blood-borne nonA, nonB viral hepatitis genome. Science 1989;224:359-362.
2. Dienstag JL: Non-A, non-B hepatitis. I. Recognition, epidemiology and clinical features. Gastroenterology 1983;85:439-462.
3. Alter JH, Hoofnagle JH: Non-A, non-B hepatitis: Observations on the first decade; in Vyas GN, Dienstag JL, Hoofnagle JH (eds): Viral Hepatitis and Liver Disease. New York, Grune & Stratton, 1984, pp 345-354.
4. Mauser-Bunschoten EP, Bresters D, van Drimmelen AAJ, Roosendaal G, Cuypers HTM, Reesink HW, van der Poel CL, van den Berg HM, Lelie PN: Hepatitis C infection and viremia in Dutch hemophilia patients. J Med Virol 1995;45:241-246.
5. van der Poel CL, Cuypers HTM, Reesink HW, Weiner AJ, Quan S, Di Nello R, van Boven JJP, Winkel I, Mulder-Folkerts D, Exel-Oehlers PJ, Schaasberg W, Leentvaart-Kuypers A, Polito A, Houghton M, Lelie PN: Confirmation of hepatitis C virus infection by new four-antigen recombinant immunoblot assay. Lancet 1991;337:317-319.
6. Realdi G, Alberti A, Rugge M, Rigoli AM, Tremolada F, Schivazappal L, Ruol A: Long-term follow-up of acute and chronic non-A, non-B post-transfusion hepatitis: Evidence of progression to liver cirrhosis. Gut 1982;23:270-275.
7. Hay CRM, Preston FE, Triger DR, Underwood JCE: Progressive liver disease in haemophilia: An underestimated problem? Lancet 1985;i:1495-1497.
8. Ruiz J, Sangro B, Cuende JI, Beloqui O, Riezu-Boj JI, Herrero JI, Prieto J: Hepatitis B and C viral infections in patients with hepatocellular carcinoma. Hepatology 1992;16:637-641.
9. Saito I, Miyamura T, Ohbayashi A, Harada H, Katayama T, Kikuchi S, Watanabe I, Koi S, Onji M, Ohta I, Choo Q-L, Houghton M, Kuo G: Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. Proc Natl Acad Sci USA 1990;87:6547-6549.
10. Simonetti RG, Camma C, Fiorello F, Cottone M, Rapicetta M, Marino L, Fiorentino G, Craxi A, Ciccaglione A, Giuseppetti R, Stroffolini T, Pagliaro L: Hepatitis C virus infection as a risk factor for hepatocellular carcinoma in patients with cirrhosis. Ann Intern Med 1992;116:97-102.
11. Alberti A, Morsica G, Chemello L, Cavalletto D, Noventa F, Pontisso P, Ruol A: Hepatitis C viraemia and liver disease in symptom-free individuals with anti-HCV. Lancet 1992;340:697-698.
12. Prieto M, Olaso V, Verdu C, Cordoba J, Gisbert C, Rayon M, Carrasco D, Berenguer M, Higon MD, Berenguer J: Does the healthy hepatitis C virus carrier state really exist? An analysis using polymerase chain reaction. Hepatology 1995;22:413-417.
13. Salmeron FJ, Palacios A, Perez-Ruiz M, Torres C, Oyonarte S, Fernandez-Montoya A, Ruiz-Extremera A: Epidemiology, serological markers, and hepatic disease of anti-HCV ELISA-2-positive blood donors. Dig Dis Sci 1996;41:1933-1938.
14. Hoofnagle JH: The role of corticosteroids, in Szmuness W, Alter HJ, Maynard JE (eds): Viral Hepatitis. Proceedings of the 1981 International Symposium. Philadelphia, Franklin Institute Press, 1981, pp 573-583.
15. Rakela J, Redeker AG: Chronic liver disease after acute non-A, non-B viral hepatitis. Gastroenterology 1979;77:1200-1202.
16. Pappas SC, Hoofnagle JU, Young N, Straus SE, Jones EA: Treatment of chronic non-A, non-B hepatitis with acyclovir: A pilot study. J Med Virol 1985;15:1-9.
17. Hoofnagle JH, Mullen KD, Jones DB, Rustgi V, Di Bisceglie A, Peters M, Waggoner JG, Park Y, Jones EA: Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon: A preliminary report. N Engl J Med 1986;315:1575-1578.
18. Thomson BJ, Doran M, Lever AML, Webster ADB: Alpha-interferon therapy for non-A, non-B hepatitis transmitted by gammaglobulin replacement therapy. Lancet 1987;i:539-541.
19. Baron S, Dianzani F, Stanton GJ, Fleischmann WR: The Interferon System: A Current Review to 1987. Austin, University of Texas Press, 1987.
20. Tilg H: New insights into the mechanisms of interferon alfa: An immunoregulatory and antiinflammatory cytokine. Gastroenterology 1997;112:1017-1021.
21. Baron S, Tyring SK, Fleischmann WR, Coppenhaver DH, Niesel DW, Klimpel GR, Stanton GJ, Hughes TK: The interferons: Mechanisms of action and clinical applications. JAMA 1991;266: 1375-1383.
22. Dianzani F, Antonelli G, Capobianchi MR: The biological basis for clinical use of interferon. J Hepatol 1990;11:S5-S10.
23. Isaacs A, Lindenmann J: Virus interference. I. The interferon. Proc R Soc Ser B 1957;147:258-267.
24. Thomas HC, Foster GR: Treatment of hepatitis C with interferon: Mechanism of action of interferon; in Nishioka K, Suzuki H, Mishiro S, Oda T (eds): Viral Hepatitis and Liver Disease. Proceedings of the 1993 International Symposium on Viral Hepatitis and Liver Disease. Tokyo, Springer, 1994, pp 594-600.
25. Frissen J: General Introduction to the Interferons, i.e. IFN-α, in Studies on Zidovudine and Interferon-Alpha in HIV-I Infection, academical thesis; University of Amsterdam, 1996, pp 20-26.
26. Davis GL, Baiart LA, Schiff ER, Lindsay K, Bodenheimer HC Jr, Perrillo RP, Carey W, Jacobson IM, Payne J, Dienstag JL, Van Thiel DH, Tamburro C, Lefkowitz J, Albrecht J, Meschievitz C, Ortego TJ, Gibas A, Hepatitis Interventional Therapy Group: Treatment of chronic hepatitis C with recombinant α-interferon: A multicenter, randomized, controlled trial. J Hepatol 1990;11: S31-S35.
27. DiBisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murray L, Waggoner J, Goodman Z, Banks SM, Hoofnagle JH: Recombinant interferon alpha therapy for chronic hepatitis C: A randomized, double-blind, placebo-controlled trial. N Engl J Med 1989;321:1506-1510.
28. Shindo M, DiBisceglie AM, Cheung L, Shih JWK, Cristiano K, Feinstone SM, Hoofnagle JH: Decrease in serum hepatitis C viral RNA during alpha interferon therapy for chronic hepatitis C. Ann Intern Med 1991;115:700-704.
29. Makris M, Preston FE, Triger DR, Underwood JCE, Westlake L, Adelman MI: A randomized controlled trial of recombinant interferon-a in chronic hepatitis C in hemophiliacs. Blood 1991;78: 1672-1677.
30. Marcellin P, Boyer N, Giostra E, Degott C, Courouce AM, Degos F, Coppere H, Cales P, Couzigou P, Benhamou JP: Recombinant human a-interferon in patients with chronic non-A, non-B hepatitis: A multicenter, randomized, controlled trial from France. Hepatology 1991;13:393-397.
31. Tine F, Magrin S, Craxi A, Pagliaro L: Interferon for non-A, non-B chronic hepatitis: A meta-analysis of randomized clinical trials. J Hepatol 1991;13:192-199.
32. Damen M, Cuypers HTM, Zaaijer HL, Reesink HW, Schaasberg WP, Gerlich WH, Niesters HGM, Lelie PN: International collaborative study on the second EUROHEP HCV-RNA reference panel. J Virol Methods 1996;58:175-185.
33. Chemello L, Bonetti P, Cavalletto L, Talato F, Donadon V, Casarin P, Belussi F, Frezza M, Noventa F, Pontisso P, Benvegnu L, Casarin C, Alberti A, TriVeneto Viral Hepatitis Group: Randomized trial comparing three different regimens of alpha-2a-interferon in chronic hepatitis C. Hepatology 1995;22:700-706.
34. Marcellin P, Pouteau M, Martinot-Peignoux M, Degos F, Duchatelle V, Boyer N, Lemonnier C, Degott C, Erlinger S, Benhamou JP: Lack of benefit of escalating dosage of interferon alfa in patients with chronic hepatitis C. Gastroenterology 1995;109:156-165.
35. Poynard Th, Bedossa P, Chevallier M, Mathurin Ph, Lemonnier C, Trepo Ch, Couzigou P, Payen JL, Sajus M, Costa JM, Vidaud M, Chaput JC, Multicenter Study Group: A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. N Engl J Med 1995;332:1457-1462.
36. Lindsay KL, Davis GL, Schiff ER, Bodenheimer HC, Balart LA, Dienstag JL, Perrillo RP, Tamburro CH, Goff JS, Everson GT, Silva M, Katkov WN, Goodman Z, Lau JYN, Maertens G, Gogate J, Sanghvi B, Albrecht J, Hepatitis Interventional Therapy Group: Response to higher doses of interferon alfa-2b in patients with chronic hepatitis C: A randomized multicenter trial. Hepatology 1996;24:1034-1040.
37. Negro F, Baldi M, Mondardini A, Leandro G, Chaneac M, Manzini P, Abate ML, Zahm F, Dastoli G, Ballare M, Ryff J-C, Venue G, Bonino F: Continuous versus intermittent therapy for chronic hepatitis C with recombinant interferon alfa-2a. Gastroenterology 1994;107:479-485.
38. Lin R, Roach E, Zimmerman M, Strasser S, Farrell GC for the Australia Hepatitis C Study Group: Interferon alfa-2b for chronic hepatitis C: Effects of dose increment and duration of treatment on response rates. Results of the first multicenter Australian trial. J Hepatol 1995;23:487-496.
39. Martinot-Peignoux M, Marcellin P, Pouteau M, Castelnau C, Boyer N, Poliquin M, Degott C, Descombes I, Le Breton V, Milotova V, Benhamou JP, Erlinger S: Pretreatment scrum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. Hepatology 1995;22:1050-1056.
40. Reichen J, Bianchi L, Bühler H, Dolivo N, Gonvers J-J, Lavanchy D, Male P-J, Renner EL, Solioz M, Schmid M, Zimmermann A, Swiss Association for the Study of the Liver: Fixed versus titrated interferon-α 2b in chronic hepatitis C: A randomized controlled multicenter trial. J Hepatol 1996; 25:275-282.
41. Poynard Th, Leroy V, Cohard M, Thevenot Th, Mathurin Ph, Opolon P, Zarski JP: Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration. Hepatology 1996;24:778-789.
42. Davis GL, Lau JYN: Choice of appropriate end points of response to interferon therapy in chronic hepatitis C virus infections. J Hepatol 1995;22(suppl 1):110-114.
43. Chemello L, Cavalletto L, Casarin C, Bonetti P, Bernardinello E, Pontisso P, Donada C, Belussi F, Martinelli S, Alberti A, TriVeneto Viral Hepatitis Group: Persistent hepatitis C viremia predicts late relapse after sustained response to interferon-α in chronic hepatitis C. Ann Intern Med 1996; 124:1058-1060.
44. De Alava E, Camps J, Pardo-Mindan J, Garcia-Granero M, Munoz M, Sola J, Civeira MP, Vazquez CF, Castilla A, Prieto J: Histological outcome of chronic hepatitis C treated with a 12-month course of lymphoblastoid alfa interferon. Liver 1993;13:73-79.
45. Hopf U, Berg T, König V, Küther S, Heuft H-G, Lobeck H: Treatment of chronic hepatitis C with interferon alpha: Long-term follow-up and prognostic relevance of HCV genotypes. J Hepatol 1996; 24(suppl 2):67-73.
46. Rumi M, Del Ninno E, Parravicini ML, Romeo R, Soffredini R, Donato MF, Wilber J, Russo A, Colombo M: A prospective, randomized trial comparing lymphoblastoid to recombinant interferon alpha 2a as therapy for chronic hepatitis C. Hepatology 1996;24:1366-1370.
47. Schiffman ML, Hofmann CM, Luketic VAC, Sanyal AJ, Contos MJ, Mills AS: Improved sustained response following treatment of chronic hepatitis C by gradual reduction in the interferon dose. Hepatology 1996;24:21-26.
48. Brouwer JT, Nevens F, Kleter B, Elewaut A, Adler M, Brenard R, Chamuleau RAFM, Michielsen PP, Pirotte J, Hautekeete ML, Weber J, Bourgeois N, Reesink HW, Geubel AP, Niesters HGM, Hop WCJ, Hansen BE, ten Kate FJW, Bronkhorst CM, Heijtink RA, Fevery J, Schalm SW: Efficacy of interferon dose and prediction of response in chronic hepatitis C: Benelux study in 336 patients. Submitted.
49. Yuki N, Hayashi N, Kasahara A, Hagiwara H, Takehara T, Oshita M, Katayama K, Fusamoto H, Kamada T: Pretreatment viral load and response to prolonged interferon-α course for chronic hepatitis C. J Hepatol 1995;22:457-463.
50. Friedlander L, Van Thiel DH, Faruki H, Molloy PJ, Kania RJ, Hassanein T: New approach to HCV treatment: Recognition of disease process as systemic viral infection rather than as liver disease. Dig Dis Sci 1996;41:1678-1681.
51. Hakozaki Y, Shirahama T, Katou M, Nakagawa K, Oba K, Mitamura K: A controlled study to determine the optimal dose regimen of interferon-α 2b in chronic hepatitis C. Am J Gastroenterol 1995;90:1246-1249.
52. Toyoda H, Nakano S, Kumada T, Takeda I, Sugiyama K, Osada T, Kiriyama S: Effect of daily administration period of natural α-interferon in patients with chronic hepatitis C. Am J Gastroenterol 1996;91:743-747.
53. Reichard O, Foberg U, Fryden A, Mattsson L, Norkrans G, Sönnerborg A, Wejstål R, Yun Z-B, Weiland O: High sustained response rate and clearance of viremia in chronic hepatitis C after treatment with interferon-α 2b for 60 weeks. Hepatology 1994;19:280-285.
54. Weiland O, Chen M, Lindh G, Mattsson L, Schvarcz R, Sönnerborg A, Wahl M, Wejstål R, Widell A, Norkrans G: Efficacy of human leucocyte alpha-interferon treatment for chronic hepatitis C virus infection. Scand J Infect Dis 1995;27:319-324.
55. Yamada M, Fukuda Y, Koyama Y, Nakano I, Urano F, Isobe K, Takamatsu J, Imoto M, Hayakawa T: A long-term follow-up study of interferon treatment for chronic hepatitis C in Japanese patients with congenital bleeding disorders. Eur J Haematol 1996;57:165-170.
56. Yamada G, Takatani M, Kishi F, Takahashi M, Doi T, Tsuji T, Shin S, Tanno M, Urdea MS, Kolberg JA: Efficacy of interferon alfa therapy in chronic hepatitis C patients depends primarily on hepatitis C virus RNA level. Hepatology 1995;22:1351-1354.
57. Magrin S, Craxi A, Fabiano C, Marino L, Fiorentino G, Lo Iacono O, Volpes R, Di Marco V, Almasio P, Vaccaro A, Urdea MS, Wilber JC, Bonura C, Gianguzza F, Capursi V, Filiberti S, Stuyver L, Pagliaro L: HCV viraemia is more important than genotype as a predictor of response to interferon in Sicily (Southern Italy). J Hepatol 1996;25:583-590.
58. Picciotto A, Campo N, Brizzolara R, Sinelli N, Poggi G, Grasso S, Celle G: HCV-RNA levels play an important role independently of genotype in predicting response to interferon therapy. Eur J Gastroenterol Hepatol 1997;9:67-69.
59. Benvegnu L, Pontisso P, Cavalletto D, Noventa F, Chemello L, Alberti A: Lack of correlation between hepatitis C virus genotypes and clinical course of hepatitis C virus-related cirrhosis. Hepatology 1997; 25:211-215.
60. Kanazawa Y, Hayashi N, Mita E, Li T, Hagiwara H, Kasahara A, Fusamoto H, Kamada T: Influence of viral quasispecies on effectiveness of interferon therapy in chronic hepatitis C patients. Hepatology 1994;20:1121-1130.
61. Chayama K, Tsubota A, Arase Y, Saitoh S, Ikeda K, Matsumoto T, Hashimoto M, Kobayashi M, Kanda M, Morinaga T, Kumada H: Genotype, slow decrease in virus titer during interferon treatment and high degree of sequence variability of hypervariable region are indicative of poor response to interferon treatment in patients with chronic hepatitis type C. J Hepatol 1995;23: 648-653.
62. Koizumi K, Enomoto N, Kurosaki M, Murakami T, Izumi N, Marumo F, Sato C: Diversity of quasispecies in various disease stages of chronic hepatitis C virus infection and its significance in interferon treatment. Hepatology 1995;22:30-35.
63. Shindo M, Hamada K, Koya S, Arai K, Sokawa Y, Okuno T: The clinical significance of changes in genetic heterogeneity of the hypervariable region 1 in chronic hepatitis C with interferon therapy. Hepatology 1996;24:1018-1023.
64. Enomoto N, Kurosaki M, Marumo F, Sato C: Fluctuation of hepatitis C virus quasispecies in persistent infection and interferon treatment revealed by single-strand conformation polymorphism analysis. J Gen Virol 1994;75:1361-1369.
65. Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, Izumi N, Marumo F, Sato C: Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. J Clin Invest 1995;96:224-230.
66. Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, Ogura Y, Izumi N, Marumo F, Sato C: Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 1996;334:77-81.
67. Weiland O, Zhang Y-Y, Widell A: Serum HCV-RNA levels in patients with chronic hepatitis C given a second course of interferon alpha-2b treatment after relapse following initial treatment. Scand J Infect Dis 1993;25:25-30.
68. Gerken G, Teuber G, Goergen B, Meyer zum Büschenfelde KU: Interferon-alpha retreatment in chronic hepatitis C. J Hepatol 1995;22(suppl 1):118-121.
69. Rabinovitz M, Block G, Finkelstein SD: α-Interferon retreatment of patients with chronic hepatitis C Am J Gastroenterol 1996;91:1523-1526.
70. Van Thiel DU, Caraceni P, Molloy PJ, Hassanein T, Kania RJ, Gurakar A, Friedlander L: Chronic hepatitis C in patients with normal or near normal alanine aminotransferase levels: The role of interferon α2b therapy. J Hepatol 1995;23:503-50S.
71. Serfati L, Chazouilleres O, Pawlotski J-M, Andreani T, Pellet C, Poupon R: Interferon alpha therapy in patients with chronic hepatitis C and persistently normal aminotransferase activity. Gastroenterology 1996;110:291-295.
72. Reichard O, Glaumann H, Weiland O: Long-term histological outcome in patients with chronic hepatitis C treated repeatedly with interferon alpha-2b without sustained response. Scand J Infect Dis 1994;26:383-389.
73. Suou T, Hosho K, Kishimoto Y, Horie Y, Kawasaki H: Long-term decrease in serum N-terminal propeptide of type III procollagen in patients with chronic hepatitis C treated with interferon alfa. Hepatology 1995;22:426-431.
74. Manabe N, Chevallier M, Chossegros Ph, Causse X, Guerret S, Trepo Ch, Grimaud J-A: Interferon-a2b therapy reduces liver fibrosis in chronic non-A, non-B hepatitis: A quantitative histological evaluation. Hepatology 1993;18:1344-1349.
75. Hiramatsu N, Hayashi N, Kasahara A, Hagiwara FJ, Takehara T, Haruna Y, Naito M, Fusamoto H, Kamada T: Improvement of liver fibrosis in chronic hepatitis C patients treated with natural interferon alpha. J Hepatol 1995;22:135-142.
76. Ziol M, Van Nhieu JT, Roudot-Thoraval F, Metreau J-M, Deugnier Y, Dhumeaux D, Zafrani ES: A histopathological study of the effects of 6-month versus 12-month interferon α-2b therapy in chronic hepatitis C. J Hepatol 1996;25:833-841.
77. Mazzella G, Accogli E, Sottili S, Festi D, Orsini M, Salzetta A, Novelli V, Cipolla A, Fabbri C, Pezzoli A, Roda E: Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. J Hepatol 1996;24:141-147.
78. Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S, Shiomi S, Seki S, Kobayashi K, Otani S: Randomized trial of effects of interferon-α on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995;346:1051-1055.
79. Alberti A, Chemello L, Belussi F, Pontisso P, Tisminetzki S, Gerotto M, Baralle F, Simmonds P: Outcome of acute hepatitis C and role of alpha interferon therapy, in Nishioka K, Suzuki H, Mishiro S, Oda T (eds): Viral Hepatitis and Liver Disease. Proceedings of the 1993 International Symposium on Viral Hepatitis and Liver Disease. Tokyo, Springer, 1994, pp 604-606.
80. Hwang S-J, Lee S-D, Chan C-Y, Lu R-H, Lo K-J: A randomized controlled trial of recombinant interferon α-2b in the treatment of Chinese patients with acute post-transfusion hepatitis C. J Hepatol 1994;21:831-836.
81. Lampertico P, Rumi M, Romeo R, Craxi A, Soffredini R, Biassoni D, Colombo M: A multicenter randomized controlled trial of recombinant interferon-α2b in patients with acute transfusion-associated hepatitis C. Hepatology 1994;19:19-22.
82. Omata M, Yokosuka O, Takano S, Kato N, Hosoda K, Imazeki F, Tada M, Ito Y, Ohio M: Resolution of acute hepatitis C after therapy with natural beta interferon. Lancet 1991;338:914-915.
83. Takano S, Satomura Y, Omata M, Japan Acute Hepatitis Cooperative Study Group: Effects of interferon beta on non-A, non-B acute hepatitis: A prospective, randomized, controlled-dose study. Gastroenterology 1994;107:805-811.
84. Camma C, Almasio P, Craxi A: Interferon as treatment for acute hepatitis C: A meta-analysis. Dig Dis Sci 1996;41:1248-1255.
85. Viladomiu L, Genesca J, Esteban J, Allende H, Gonzalez A, Lopez-Talavera JC, Esteban R, Guardia J: Interferon-α in acute post-transfusion hepatitis C: A randomized, controlled trial. Hepatology 1992;15:767-769.
86. Ohnishi K, Nomura F, Nakano M: Interferon therapy for acute posttransfusion non-A, non-B hepatitis: Response with respect to anti-hepatitis C virus antibody status. Am J Gastroenterol 1991; 86:1041-1049.
87. Komatsu H, Fujisawa T, Inui A, Miyakawa Y, Onoue M, Sekine I, Hanada R, Yamamoto K: Efficacy of interferon in treating chronic hepatitis C in children with a history of acute leukemia. Blood 1996;87:4072-4075.
88. Iorio R, Pensati P, Porzio S, Fariello I, Guida S, Vegnente A: Lymphoblastoid interferon alfa treatment in chronic hepatitis C. Arch Dis Child 1996;74:152-156.
89. Bortolotti F, Giachino R, Vajro P, Barbera C, Crivellaro C, Alberti A, Nebbia G, Zancan L, De Moliner L, Bertolini A, Balli F, Callea F: Recombinant interferon-alfa therapy in children with chronic hepatitis C. Hepatology 1995;22:1623-1627.
90. Gomez-Rubio M, Porres JC, Castillo I, Quiroga JA, Moreno A, Carreno V: Prolonged treatment (18 months) of chronic hepatitis C with recombinant α-interferon in comparison with a control group. J Hepatol 1990;11:S63-S67.
91. Shakil AO, DiBisceglie AM, Hoofnagle JH: Seizures during alpha interferon therapy. J Hepatol 1996;24:48-51.
92. Sheremata WA, Taylor JR, Elgart GW: Severe necrotizing cutaneous lesions complicating treatment with interferon beta-1b. N Engl J Med 1995;332:1584.
93. Aulitzky WE, Tilg H, Vogel W, Aulitzki W, Berger M, Gastl G, Herold M, Huber C: Acute hematologic effects of interferon alpha, interferon gamma, tumour necrosis factor alpha and interleukin 2. Ann Hematol 1991;62:25-31.
94. Hoofnagle JH: Thrombocytopenia during interferon-alpha therapy. JAMA 1991;266:849.
95. Abdi EA, Brien W, Venner PM: Auto-immune thrombocytopenia related to interferon therapy. Scand J Haematol 1986;36:515-519.
96. Renault PF, Hoofnagle JH, Park Y, Mullen KD, Peters M, Jones B, Rustgi V, Jones EA: Psychiatric complications of long-term interferon alpha therapy. Arch Intern Med 1987;147:1577-1580.
97. McDonald EM, Mann AH, Thomas HC: Interferons as mediators of psychiatric morbidity. Lancet 1987;ii:1175-1178.
98. Burman P, Karlsson FA, Oberg K, Alm G: Autoimmune thyroid disease in interferon-treated patients. Lancet 1985;ii:100-101.
99. Burman P, Totterman TH, Oberg K, Karlsson FA: Thyroid autoimmunity in patients on long-term therapy with leucocyte-derived interferon. J Clin Endocrinol Metab 1986;63:1086-1090.
100. Giles FJ, Worman CP, Jewell AP, Goldstone AH: Recombinant alpha-interferons, thyroid irradiation and thyroid disease. Acta Haematol 1991;85:160-163.
101. Saracco G, Touscoz A, Durazzo M, Rosina F, Donegani E, Chiandussi L, Gallo V, Petrino R, De Micheli AG, Solinas A, Deplano A, Tocco A, Cossu PA, Pintus C, Verme G, Rizzetto M: Autoantibodies and response to α-interferon in patients with chronic viral hepatitis. J Hepatol 1990;11: 339-343.
102. Fattovich G, Betterle C, Brollo L, Pedini B, Giustina G, Realdi G, Alberti A, Ruol A: Autoantibodies during α-interferon therapy for chronic hepatitis B. J Med Virol 1991;34:132-135.
103. Antonelli G, Currenti M, Turriziani E, Dianzani F: Relative frequency of nonneutralizing antibodies to interferon (IFN) in hepatitis patients treated with different IFN-α preparations. J Infect Dis 1992;165:593-594.
104. Craxi A, Di Marco V, Volpes R, Palazzo U: Anti-alpha interferon antibodies after alpha interferon treatment in patients with chronic viral hepatitis. Hepatogastroenterology 1988;35:304-305.
105. Spiegel RJ, Spicehandler JR, Jacobs SL, Oden EM: Low incidence of serum neutralizing factors in patients receiving recombinant alpha-2b interferon (Intron A). Am J Med 1986;80:223-228.
106. Hanley JP, Jarvis LM, Simmonds P, Ludlam CA: Development of anti-interferon antibodies and breakthrough hepatitis during treatment for HCV infection in haemophiliacs. Br J Haematol 1996; 94:551-556.
107. Kawano T, Shigehira M, Uto H, Nakama T, Kato J, Hayashi K, Maruyama T, Kuribayashi T, Chuman T, Futami T, Tsubouchi H: Retinal complications during interferon therapy for chronic hepatitis C. Am J Gastroenterol 1996;91:309-313.
108. Marcellin P, Colin JF, Boyer N, Bernuau J, Degott C, Hirschauer C, Benhamou JP: Fatal exacerbation of chronic hepatitis B induced by recombinant alpha-interferon. Lancet 1991;338:828.
109. Wandl UB, Kloke O, Niederle N: Liver failure due to recombinant alpha interferon for chronic myelogenous leukemia. Lancet 1992;339:123-124.
110. Janssen HLA, Schalm SW, Nevens F, Fevery J, Brouwer JT, Marcellin P, Sanchez-Tapias JM, Craxi A, Hadziyannis S, European Concerted Action on Viral Hepatitis (EUROHEP): Fatal decompensation of chronic viral hepatitis associated with alpha-interferon treatment. Neth J Med 1993;42:A8.
111. Farhat BA, Johnson PJ, Williams R: Hazards of interferon treatment in patients with autoimmune chronic active hepatitis. J Hepatol 1994;20:560-561.
112. Bellary S, Schiano T, Hartman G, Black M: Chronic hepatitis with combined features of autoimmune chronic hepatitis and chronic hepatitis C: Favourable response to prednisone and azathioprine. Ann Intern Med 1995;123:32-34.
113. Todros L, Saracco G, Durazzo M, Abate ML, Touscoz G, Scaglione L, Verme G, Rizzetto M: Efficacy and safety of interferon alfa therapy in chronic hepatitis C with autoantibodies to liver-kidney microsomes. Hepatology 1995;22:1374-1378.
114. Patterson JL, Fernandez-Larsson R: Molecular mechanism of action of ribavirin. Rev Infect Dis 1990;12:1139-1145.
115. Streeter DG, Witkovski JT, Khare GP, Sidwell RW, Bauer RJ, Robins RL, Simon LN: Mechanism of action of 1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (Virazole), a new broad-spectrum antiviral agent. Proc Natl Acad Sci USA 1973;70:1174-1178.
116. Patki S, Gupta P: Evaluation of ribavirin in the treatment of acute hepatitis. Chemotherapy 1982; 28:298-303.
117. Roberts RB, Dickinson GM, Heseltine PNR, Leedom JM, Mansell PWA, Rodriquez S, Johnson KM, Lubina JA, Makuch RW, Ribavirin-LAS Collaborative Group: A multicenter clinical trial of oral ribavirin in HIV-infected patients with lymphadenopathy. J Acquir Immune Defic Syndr 1990;3:884-892.
118. Ray CG, Icenogle TB, Minnich LL, Copeland JG, Grogan TM: The use of intravenous ribavirin to treat influenza virus-associated acute myocarditis. J Infect Dis 1989;159:829-836.
119. McCormiak JB, King IJ, Webb PA: Lassa fever-effective therapy with ribavirin. N Engl J Med 1986;314:20-26.
120. Camps J, Garcia N, Riezu-Boj JI, Civeira MP, Prieto J: Ribavirin in the treatment of chronic hepatitis C unresponsive to alpha interferon. J Hepatol 1993;19:408-412.
121. Reichard O, Yun Z-B, Sönnerborg A, Weiland O: Hepatitis C viral RNA titers in serum prior to, during, and after oral treatment with ribavirin for chronic hepatitis C. J Med Virol 1993;41:99-102.
122. DiBisceglie AM, Conjeevaram HS, Fried MW, Sallie R, Park Y, Yurdaydin C, Swain M, Kleiner DE, Mahaney K, Hoofnagle JH: Ribavirin as therapy for chronic hepatitis C: A randomized, double blind, placebo-controlled trial. Ann Intern Med 1995;123:897-903.
123. Dusheiko G, Main J, Thomas H, Reichard O, Lee Ch, Dhillon A, Rassam S, Fryden A, Reesink HW, Bassendine M, Norkrans G, Cuypers HTM, Lelie PN, Telfer P, Watson J, Weegink Ch, Sillekens P, Weiland O: Ribavirin treatment for patients with chronic hepatitis C: Results of a placebo-controlled study. J Hepatol 1996;25:591-598.
124. Lai M-Y, Kao J-H, Yang P-M, Wang J-T, Chen P-J, Chan K-W, Chu J-S, Chen D-S: Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C. Gastroenterology 1996;111:1307-1312.
125. Chemello L, Cavalletto L, Bernardinello E, Guido M, Pontisso P, Alberti A: The effect of interferon alfa and ribavirin combination therapy in naive patients with chronic hepatitis C. J Hepatol 1995; 23(suppl 2):8-12.
126. Brillanti S, Miglioli M, Barbara L: Combination antiviral therapy with ribavirin and interferon alfa in interferon alfa relapsers and non-responders: Italian experience. J Hepatol 1995;23(suppl 2):13-16.
127. Brouwer JT, Nevens F, Michielsen P, Hautekeete ML, Chamuleau RAFM, Adler M, Delwaide J, Heijtink RA, Schalm SW, Benelux Study Group on Hepatitis C Treatment: What options are left when hepatitis C does not respond to interferon? Placebo-controlled Benelux multicenter retreatment trial on ribavirin monotherapy versus combination with interferon (abstract). J Hepatol 1994; 21(suppl 1):S17.
128. Schvarcz R, Ando Y, Sönnerborg A, Weiland O: Combination treatment with interferon alfa-2b and ribavirin for chronic hepatitis C in patients who have failed to achieve sustained response to interferon alone: Swedish experience. J Hepatol 1995;23(suppl 2):17-21.
129. Braconier JH, Paulsen O, Engman K, Widell A: Combined alpha-interferon and ribavirin treatment in chronic hepatitis C: A pilot study. Scand J Infect Dis 1995;27:325-329.
130. Villa E, Trande P, Grottola A, Buttafoco P, Rebecchi AM, Stroffolini T, Callea F, Merighi A, Camellini L, Zoboli P, Cosenza R, Miglioli L, Loria P, Iori R, Carulli N, Manenti F: Alpha but not beta interferon is useful in chronic active hepatitis due to hepatitis C virus: A prospective, double blind, randomized study. Dig Dis Sci 1996;41:1241-1247.
131. Boucher E, Jouanolle H, Andre P, Ruffault A, Guyader D, Moirand R, Turlin B, Jacquelinet Ch, Brissot P, Deugnier Y: Interferon and ursodeoxycholic acid combined therapy in the treatment of chronic viral C hepatitis: Results from a controlled randomized trial in 80 patients. Hepatology 1995;21:322-327.
132. Takano S, Ito Y, Yokosuka O, Ohio M, Uchiumi K, Hirota K, Omata M: A multicenter randomized controlled dose study of ursodeoxycholic acid for chronic hepatitis C. Hepatology 1994;20:558-564.
133. Angelico M, Gandin C, Pescarmona E, Rapicetta M, Del Vecchio C, Bini A, Spada E, Baroni CD, Capocaccia L: Recombinant interferon-α and ursodeoxycholic acid versus interferon-α alone in the treatment of chronic hepatitis C: A randomized clinical trial with long-term follow-up. Am J Gastroenterol 1995;90:263-269.
134. Hoofnagle JH, DiBisceglie AM: The treatment of chronic viral hepatitis; in Wood AJJ (ed): Drug Therapy. N Engl J Med 1997;336:347-356.
135. Carreno V, Quiroga JA: New and forthcoming therapies for viral hepatitis. J Hepatol 1996;24(suppl 2): 74-76.
136. Calleja JL, Albillos A, Cacho G, Iborra J, Abreu L, Escartin P: Interferon and prednisone therapy in chronic hepatitis C with non-organ-specific antibodies. J Hepatol 1996;24:308-312.
137. Kim JL, Morgenstern KA, Lin C: Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide. Cell 1996;87:343-355.
138. Feray C, Gigou M, Samuel D, Paradis V, Wilber J, David MF, Urdea M, Reynes M, Brechot Ch, Bismuth H: The course of hepatitis C virus infection after liver transplantation. Hepatology 1994; 20:1137-1143.
139. Gretch DR, Bacchi CE, Corey L, Dela Rosa C, Lesniewski RR, Kowdley K, Gown A, Frank I, Perkins JD, Carithers RL: Persistent hepatitis C virus infection after liver transplantation: Clinical and virological features. Hepatology 1995;22:1-9.
140. Böker KHW, Dalley G, Bahr MJ, Maschek H, Tillmann HL, Trautwein Ch, Oldhaver K, Bode U, Pichlmayr R, Manns MP: Long-term outcome of hepatitis C virus infection after liver transplantation. Hepatology 1997;25:203-210.
141. Ascher NL, Lake JR, Emond J, Roberts J: Liver transplantation for hepatitis C virus-related cirrhosis. Hepatology 1994;20:24S-27S.
142. Chazouilleres O, Kim M, Combs C, Ferrell L, Bacchetti P, Roberts J, Ascher NL, Neuwald P, Wilber J, Urdea M, Quan S, Sanchez-Pescador R, Wright TL: Quantitation of hepatitis C virus RNA in liver transplant recipients. Gastroenterology 1994;106:994-999.
143. Gane EJ, Portmann BC, Naoumov NV, Smith HM, Underhill JA, Donaldson PT, Maertens G, Williams R: Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996;334:815-820.
144. Schluger LK, Sheiner PA, Thung SN, Lau JYN, Min A, Wolf DC, Fiel I, Zhang D, Gerber MA, Miller CM, Bodenheimer HC: Severe recurrent cholestatic hepatitis C following orthotopic liver transplantation. Hepatology 1996;23:971-976.
145. Feray C, Samuel D, Gigou M, Paradis V, David MF, Lemonnier C, Reynes M, Bismuth H: An open triall of interferon alfa recombinant for hepatitis C after liver transplantation: Antiviral effects and risk of rejection. Hepatology 1995;22:1084-1089.
146. Wright TL, Combs C, Kim M, Ferrell L, Bacchetti P, Ascher N, Roberts J, Wilber J, Sheridan P, Urdea M: Interferon-α therapy for hepatitis C virus infection after liver transplantation. Hepatology 1994; 20: 773-779.